Treatment of muscle-invasive bladder cancer in Canada: A survey of genitourinary medical oncologists and urologists

Tina Hsu, MD, FRCPC;* Peter C. Black, MD, FACS, FRCS;† Kim N. Chi, MD, FRCPC;‡ Christina M. Canil, MD, FRCPC;§ Bernhard J. Eigl, MD, FRCPC; Girish Kulkarni, MD, PhD, FRCS; Scott North, MD, FRCPC; Lori Wood, MD, FRCPC;¶ Alexandre R. Zlotta, MD, PhD, FRCS; Anthea Lau; Tony Panzarella, MSc, Pstat; Srikala S. Sridhar, MD, MSc, FRCPC

*University of Toronto, Toronto ON; †University of British Columbia, Vancouver BC; ‡British Columbia Cancer Agency, Vancouver BC; §Ottawa Regional Cancer Centre, Ottawa ON; ¶Cross Cancer Institute, Edmonton AB; ¶Queen Elizabeth II Health Sciences Centre, Halifax NS; ¶Princess Margaret Cancer Centre, Toronto ON

Published online October 13, 2014.

Abstract

Introduction: Uptake of neoadjuvant chemotherapy (NC) for muscle invasive bladder cancer (MIBC) has been low despite evidence of a survival benefit. The primary aim of this study was to better understand why the rates are low and determine what factors specifically influence the decision to recommend NC for MIBC.

Methods: A 31-question survey was emailed between 2009 and 2011 to medical oncologists belonging to the Canadian Association of Genitourinary Medical Oncologists (CAGMO); and to urologists belonging to the Canadian Urologic Oncology Group (CUOG). We gathered data on practice characteristics, referrals for NC, factors influencing NC use, and chemotherapy regimens offered. Responses were summarized using descriptive statistics.

Results: In total, 26/30 (87%) medical oncologists and 25/84 (30%) urologists, who were primarily academic, completed the survey. Most clinicians (medical oncologists 96%, urologists 88%) recommended NC for MIBC, because they considered it to be the standard of care, but most medical oncologists saw ≤6 referrals annually. Performance status, presence of comorbidities and renal function were key considerations in offering NC. NC was not offered if performance status ≥2 (medical oncologists 38%, urologists 44%), age >80 (medical oncologists 46%, urologists 39%), or glomerular filtration rate ≤40 mL/min (medical oncologists 81%, urologists 50%).

Conclusions: Most academic clinicians in Canada believe that cisplatin-based combination NC is the standard of care for MIBC and recommend it for patients with adequate performance status and renal function. Using a multidisciplinary approach to treat this disease may be one strategy to increase referral rates for NC and uptake of NC.

Introduction

According to the Canadian Cancer Society, bladder cancer is the fifth most common cancer overall, accounting for 7800 cases/year; of these cases, about 15% to 20% are muscle invasive bladder cancers (MIBC).1 For these patients, radical cystectomy arguably remains the standard of care. However, 5-year overall survival rates following radical cystectomy alone are only 50%, and fall to 37% and 31% in patients with extravesical extension and lymph node involvement, respectively.2,3 Recurrences often occur distantly, suggesting the presence of micrometastatic disease at the time of surgery. Attempts to improve outcomes have therefore focused on the use of neoadjuvant cisplatin-based combination chemotherapy to improve overall survival.4

In the MRC/EORTC (Medical Research Council/European Organization for Research and Treatment of Cancer) trial, 976 patients were randomized to 3 cycles of cisplatin, methotrexate and vinblastine or no neoadjuvant chemotherapy (NC) followed by cystectomy or radiation. NC had an absolute survival benefit of 5% and a relative risk reduction in death of 16% at 10 years.5 Similarly, the SWOG 8710 trial which randomized 317 MIBC patients to 3 cycles of methotrexate, vinblastine, doxorubicin, cisplatin (MVAC) followed by cystectomy or cystectomy alone, showed a median survival of 77 months with NC versus 46 months without NC; and a 5-year overall survival of 57% versus 43% (p = 0.06).6 Furthermore, a meta-analysis of 3005 patients from 11 randomized trials has also shown a 5% absolute overall survival benefit at 5 years (50% vs. 45%) with cisplatin-based combination NC.4

Despite this Level 1 evidence, NC uptake has historically been low.7 However, recent studies suggest NC uptake may be increasing. An American study of 5692 patients treated from 2006 to 2010 showed a NC rate of 10.1% in
2006, which increased to 20.8% by 2010. Similarly, an Australian study showed an uptake of 17% increasing over time. Nonetheless, in the context of Level 1 evidence, these rates are low, and these retrospective studies do not help us understand why.

The primary aim of this study was to better understand why uptake is low and determine what factors influence the decision to recommend NC by surveying medical oncologists and urologists.

**Methods**

A 31-question survey covering 5 domains (practice characteristics; referrals for bladder cancer and NC; reasons to not offer NC; chemotherapy used) was developed. Five medical oncologists reviewed questions to ensure content and face validity and feedback was incorporated into the final survey (Appendix 1; http://journals.sfu.ca/cuaj/index.php/journal/article/view/2111). The survey was sent electronically to medical oncologists, belonging to the Canadian Association of Genitourinary Medical Oncologists (CAGMO), and to urologists (excluding chemotherapy-specific questions) belonging to the Canadian Urologic Oncology Group (CUOG). Both groups were contacted several times to enhance the response rate. Respondents completing the survey voluntarily gave implied consent, so formal consent forms were not required.

Responses were summarized using proportions and percentages. All percentages were calculated as a function of the number of respondents for each question.

**Results**

**Respondent characteristics**

The response rate for medical oncologists was 87% (26/30): 92% were academic, 42% focused primarily on GU cancers (Table 1). The response rate for urologists was 30% (25/84): 84% were academic, 72% focused primarily on genitourinary (GU) cancers.

**Referrals**

Most medical oncologists (88%) and urologists (63%) referred ≤6 cases/year for NC, though some urologists

---

_Fig. 1. Age and performance status of new bladder cancer referrals received by medical oncologists (left - all bladder cancer referrals, right - referrals for neoadjuvant chemotherapy). ECOG: Eastern Cooperative Oncology Group._

---
referred more frequently (8% referred 10 cases/year; 8% referred 15 cases/year; and 8% at ≥20 cases/year). The highest referral rates occurred in the setting of a multidisciplinary clinic and/or care pathway (Table 1).

We illustrated the age and performance status of all referrals and referrals for NC as reported by medical oncologists (Fig. 1) and urologists (Fig. 2). Younger patients (especially <50) and patients with better performance status were more commonly referred for NC. Patients with T2a tumours were never/rarely offered NC (medical oncologists 48% never; urologists 40% never); compared to patients with T3b disease (Fig. 3).
Most clinicians report offering NC, because they considered it to be the standard of care (medical oncologists 96%, urologists 88%) (Fig. 4).

Factors influencing decision to use NC

Figure 5 shows the relative importance of patient and tumour characteristics for medical oncologists and urologists. Figure 6 shows the threshold at which clinicians would not offer NC. Performance status was the most important factor – about 40% did not offer NC to patients with Eastern Cooperative Oncology Group (ECOG) performance status ≥2.10 Most medical oncologists (81%) and urologists (50%) report that they would not offer NC if glomerular filtration rate (GFR) was ≤20 to 40 mL/min. Age was not a key factor, yet 46% of medical oncologists and 39% of urologists did not offer NC to patients who were ≥80 years old. T-stage was not a major consideration for 39% of medical oncologists and 21% of urologists. NC was commonly offered to patients with T3 disease, but not offered to those with T2a disease (medical oncologists 31%, urologists 46%) (Fig. 6, part D).

Chemotherapy regimens used

All medical oncologists reported using gemcitabine/cisplatin (GC) neoadjuvantly. Other regimens included dose-dense methotrexate/vinblastine/adriamycin/cisplatin (MVAC) (19%), gemcitabine/carboplatin (8%), standard MVAC (4%) and gemcitabine/cisplatin/paclitaxel (4%). In the presence of renal insufficiency (GFR <40-60 mL/min), 8% of medical oncologists split cisplatin over days 1 and 8, 8% modified the dose, 21% substituted carboplatin for cisplatin, while 17% forewent NC altogether.

### Table 1. Medical oncology and urologist respondent practice characteristics

<table>
<thead>
<tr>
<th></th>
<th>Medical oncologists (n = 26), no. (%)</th>
<th>Urologists (n = 25), no. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Academic</td>
<td>24 (92.3)</td>
<td>21 (84.0)</td>
</tr>
<tr>
<td>Time in clinical practice</td>
<td></td>
<td></td>
</tr>
<tr>
<td>25-50%</td>
<td>6 (23.1)</td>
<td>2 (8.0)</td>
</tr>
<tr>
<td>50-75%</td>
<td>15 (57.7)</td>
<td>10 (40.0)</td>
</tr>
<tr>
<td>&gt;75%</td>
<td>5 (19.2)</td>
<td>13 (52.0)</td>
</tr>
<tr>
<td>Years in practice</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;5 years</td>
<td>5 (19.2)</td>
<td>3 (12.0)</td>
</tr>
<tr>
<td>5-9 years</td>
<td>7 (26.9)</td>
<td>4 (16.0)</td>
</tr>
<tr>
<td>≥10 years</td>
<td>14 (53.8)</td>
<td>18 (72.0)</td>
</tr>
<tr>
<td>Practice dedicated to GU oncology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;10%</td>
<td>1 (3.8)</td>
<td>1 (4.0)</td>
</tr>
<tr>
<td>10-25%</td>
<td>8 (30.8)</td>
<td>4 (16.0)</td>
</tr>
<tr>
<td>25-50%</td>
<td>6 (23.1)</td>
<td>2 (8.0)</td>
</tr>
<tr>
<td>&gt;50%</td>
<td>11 (42.3)</td>
<td>18 (72.0)</td>
</tr>
<tr>
<td>Bladder cancer referrals (patients/year)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5-10</td>
<td>4 (15.4)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>11-15</td>
<td>10 (38.5)</td>
<td>1 (4.0)</td>
</tr>
<tr>
<td>16-20</td>
<td>5 (19.2)</td>
<td>3 (12.0)</td>
</tr>
<tr>
<td>&gt;20</td>
<td>7 (26.9)</td>
<td>21 (84.0)</td>
</tr>
<tr>
<td>Bladder cancer referrals for neoadjuvant management (patients/year)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>0 (0)</td>
<td>2 (8.3)</td>
</tr>
<tr>
<td>1-2</td>
<td>8 (32.0)</td>
<td>5 (20.3)</td>
</tr>
<tr>
<td>3-4</td>
<td>7 (28.0)</td>
<td>6 (25.0)</td>
</tr>
<tr>
<td>5-6</td>
<td>7 (28.0)</td>
<td>2 (8.3)</td>
</tr>
<tr>
<td>&gt;6</td>
<td>3 (12.0)</td>
<td>9 (37.5)</td>
</tr>
<tr>
<td>Missing</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>

\[Fig. 4. Goals of neoadjuvant chemotherapy as reported by (a) medical oncologists and (b) urologists.\]
Barriers to NC

Additional barriers to NC use included the belief that NC does not improve survival, concern that disease progression during NC could render patients incurable, and difficulty getting community medical oncologists to administer NC.

Discussion

Despite evidence demonstrating a survival benefit of NC in MIBC, uptake remains low. Understanding and addressing the reasons for low uptake may lead to higher rates of NC use and possibly improved outcomes.

In this survey of Canadian GU medical oncologists and urologists, most respondents were academic and practicing ≥10 years. Overall, NC was offered by most respondents based mostly on the belief that NC is the standard of care for MIBC. However, 88% and 62.5% of medical oncologists and urologists, respectively, still reported seeing or referring ≤6 patients/year for NC. Previous studies suggest that referral rates to a medical oncologist are generally low and may account for non-receipt of NC.11-13 Prior studies evaluating NC in MIBC suggest that the implementation of a standardized multidisciplinary approach increases the referral rate and the uptake of NC in eligible patients, even in the academic setting.11,13 Respondents who saw and referred the highest cases of NC annually reported doing so in the context of a multidisciplinary clinic.

Our results suggest that a multidisciplinary approach, which is not a new concept in oncology, may increase NC uptake. This approach may promote discussion between medical oncologists and urologists and provide patients with a balanced opinion of risks and benefits of NC upfront. Alternatively, it may be more feasible to automatically refer all patients with agreed upon characteristics (i.e., performance status 0-1, limited comorbidities, and adequate renal function) for NC. Overall, we found general agreement between medical oncologists and urologists on characteristics of patients eligible for NC. In fact a consensus guideline, developed by Canadian medical oncologists and urologists, has suggested a streamlined multidisciplinary referral process to standardize treatment of MIBC and increase NC uptake.14

The discrepancy between willingness to administer NC and actual use may also reflect selective utilization of NC due to patient factors, such as poor performance status, presence of comorbidities and renal dysfunction, all of which are prevalent in this population and were key reasons for not recommending NC in other studies.15-17 Studies suggest that up to 33% to 47% of patients have renal dysfunction (CrCl<60 mL/min) preoperatively which may preclude NC.15,18 In our study, for patients with mild renal dysfunction, medical oncologists reported they may modify the chemotherapy dose, schedule or regimen, though the evidence supporting these approaches is less robust. Currently, it is unclear if it is better for patients with MIBC to receive modified cisplatin-based combination chemotherapy or forego NC altogether. Clearly, more studies are needed.

Although age was less important in our study, patients referred for NC tended to be younger. This is similar to other studies showing age ≥75 precludes referral to a medical oncologist due to concerns over chemotherapy tolerability, a higher prevalence of comorbidities (50% of those ≥75 have more than 4 comorbidities) and renal dysfunction with increasing age.18,19 Admittedly there were few patients in their 70s and 80s included in prospective NC studies and as a result the data supporting its use in these patients are less robust.5,6 One study, however, suggested that toxicities were comparable in patients ≥70 and <70 receiving NC.20

Fig. 5. Factors influencing decision not to administer neoadjuvant chemotherapy for (a) medical oncologists and (b) urologists.
As the median age of bladder cancer patients is 73 and >20% are over 80, further studies in older adults and cisplatin-ineligible patients are clearly needed.

Tumour factors also play a role in decision-making. Although NC studies included patients with T2-T4a N0 disease, our results suggest that many clinicians rarely offer NC to patients with T2-disease. This perhaps reflects a belief that these patients have a better prognosis and derive less relative benefit from NC. Discrepancies between clinical and pathological staging is a major issue in MIBC with upstaging post-cystectomy occurring in almost 30% to 61% of cases. One of the strongest risk factors for upstaging is T2-disease. As 20% to 30% of patients with pT2 disease relapse distantly and the SWOG-8710 trial reported a median 30-month improvement in overall survival with NC in patients with T2-tumours, there is a strong rationale to use NC even in these patients.

An alternate strategy is to use a risk-stratified approach, in which patients with high-risk features receive NC and low-risk patients who are upstaged receive adjuvant chemotherapy (AC). However, local expertise, experience with this approach and available diagnostic imaging and resources should be considered. It should be noted that less than a third of patients who were upstaged received AC – this is in line with data indicating that NC is more often successfully administered than AC (87%-97% vs. 50%-77%), perhaps because of postoperative complications, poor performance status and renal insufficiency. As those receiving AC had better disease-specific survival than those who did not, the inability to administer chemotherapy adjuvantly is a significant concern.

Adoption of new treatment paradigms can be challenging. Even within this group of GU oncology specialists, 8% to 12% of clinicians do not offer NC – some expressed skepticism about the value of NC and were concerned about surgical delay in those not responding to NC. This has been cited as a reason for low NC uptake. The use of mid-treatment staging to assess treatment response and to decide whether to continue NC or proceed to surgery, as well as the development of better predictors of chemosensitivity, may help alleviate these concerns and increase NC uptake.

This study has several limitations. As most respondents worked in academic centres and belonged to 2 professional societies focused on urologic cancers, our results may not
be generalizable to the community setting where many bladder cancer cases are seen. Similarly the response rate for urologists was also low, which could also affect results. We acknowledge that the tumour substaging (e.g., T2a vs. T2b) used in our survey may not be useful clinically as this distinction may be difficult to discern preoperatively. Lastly, patient preference for immediate definitive therapy and/or to not receive chemotherapy was not accounted for in our study.11

Conclusions

To our knowledge, this is the first Canadian study of medical oncologists and urologists attempting to understand why NC use in MIBC is low. We found that most clinicians, who specialize in GU cancers and work in academic centers, do believe that NC is the standard of care for MIBC. Medical oncologists will offer NC to MIBC patients with adequate performance status, limited comorbidities and adequate renal function; however, these patients are not always referred prior to surgery. One potential approach to increase referral rate for NC may be to manage MIBC using a multidisciplinary approach. If lack of volume and experience are factors in the low uptake of NC, consultation at a tertiary centre or discussion at a multidisciplinary tumour board may also be helpful.

Competing interests: Dr. Hsu, Dr. Engl, Dr. North, Dr. Lau, Dr. Panzarella and Dr. Sidhar all declare no competing financial or personal interests. Dr. Block is a member of the advisory boards for Amgen, Janssen, Ferring and Astellas. He has also received a commercial grant from GenomicDX. He is currently participating in a clinical trial with Ferring, Astellas, GSX and Janssen. Dr. Chi has received a commercial grant from Astellas, Astro Zeneca, Amgen, Bayer, Janssen, Millennium, Novartis, Oncogenex and Sanofi. Dr. Canil has participated in Advisory Boards for Pfizer, Astellas and Amgen. She has received speaking fees for Janssen and Astellas and travel grants from Novartis and Janssen. She has been an investigator in clinical trials for Pfizer, Janssen, Astellas and Sanofi Oncology. Dr. Kulkami has received a commercial grant from Astellas and he is currently participating in a clinical trial with Spectrum Pharmaceuticals. Dr. Wood is a member of the advisory boards for Pfizer, Astellas and Janssen. She is also participating in clinical trials with GSX, BMS, Astellas and Novartis. Dr. Zlotto is a member of the advisory boards for Amgen, Ferring and Astellas. He has received commercial grants from Sanofi and Red Leaf Medical. He is also participating in a clinical trial with Sanofi Aventis.

This paper has been peer-reviewed.

References


Correspondence: Dr. Srikala S. Sridhar, Medical Oncologist, Princess Margaret Hospital, Assistant Professor, University of Toronto, Toronto, ON M5G 2M9; srikala.sridhar@uhn.ca